Domainex

Domainex operates as a preclinical contract research organization (CRO) specializing in integrated drug discovery services for pharmaceutical and biotechnology partners. Its core model is a hybrid outsourcing approach, providing a full suite of capabilities from biosciences (protein production, assay development) through chemistry (medicinal, synthetic) and DMPK, supported by computational chemistry and AI/ML. With a strong track record of repeat business and a science-driven philosophy, Domainex aims to accelerate and de-risk early-stage research for its clients, delivering high-quality leads efficiently.

Integrated drug discovery platform combining experimental biosciences (protein production, assay development, structural biology) and chemistry with computational chemistry, AI/ML, and a proprietary Direct-to-Biology (D2B) synthesis/testing system. Supports small molecules, biotherapeutics, and novel modalities like targeted protein degradation.

Domainex competes with large, full-service CROs (e.g., Charles River, Evotec) and numerous niche discovery specialists. It differentiates through its integrated 'hybrid' partnership model, deep expertise in challenging target classes, and the integration of its D2B platform and computational/AI tools to accelerate the DMTA cycle.